Cargando…

Clinical laboratory experience of blood CRIM testing in infantile Pompe disease

Cross-reactive immunological material (CRIM) status is an important prognostic factor in patients with infantile Pompe disease (IPD) being treated with enzyme replacement therapy. Western blot analysis of cultured skin fibroblast lysates has been the gold standard for determining CRIM status. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bali, Deeksha S., Goldstein, Jennifer L., Rehder, Catherine, Kazi, Zoheb B., Berrier, Kathryn L., Dai, Jian, Kishnani, Priya S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674832/ https://www.ncbi.nlm.nih.gov/pubmed/26693141 http://dx.doi.org/10.1016/j.ymgmr.2015.10.012

Ejemplares similares

CRIM-negative infantile Pompe disease: Characterization of immune responses in patients treated with ERT monotherapy
por: Berrier, Kathryn L., et al.
Publicado: (2015)

Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy
por: Desai, Ankit K., et al.
Publicado: (2019)

A Race Against Time—Changing the Natural History of CRIM Negative Infantile Pompe Disease
por: Gupta, Punita, et al.
Publicado: (2020)

Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers
por: Stenger, Elizabeth O., et al.
Publicado: (2015)

Development of a clinically validated in vitro functional assay to assess pathogenicity of novel GAA variants in patients with Pompe disease identified via newborn screening
por: Goomber, Shelly, et al.
Publicado: (2022)

A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation
por: Curelaru, Shiri, et al.
Publicado: (2022)

Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via Newborn Screening: The benefits of early treatment with enzyme replacement therapy and immune tolerance induction
por: Li, Cindy, et al.
Publicado: (2021)

Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease
por: van Gelder, Carin M., et al.
Publicado: (2014)

Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT
por: Banugaria, Suhrad G., et al.
Publicado: (2013)

Pompe disease- experience from South India
por: Lingappa, Lokesh, et al.
Publicado: (2013)

Long term outcome and clinical experience on immune tolerance induction therapies in infantile Pompe disease
por: Austin, Stephanie, et al.
Publicado: (2013)

Adenotonsillectomy should be avoided whenever possible in infantile-onset Pompe disease
por: Jones, Harrison N., et al.
Publicado: (2020)

Screening data from 19 patients with late‐onset Pompe disease for a phase I clinical trial of AAV8 vector‐mediated gene therapy
por: Hannah, William B., et al.
Publicado: (2023)

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
por: Prater, Sean N, et al.
Publicado: (2013)

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease
por: Kazi, Zoheb B., et al.
Publicado: (2018)

Un crim : i altres contes /
por: Calders, Pere, 1912-
Publicado: (1995)

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort
por: Desai, Ankit K., et al.
Publicado: (2020)

Behavioral, social and school functioning in children with Pompe disease
por: Korlimarla, Aditi, et al.
Publicado: (2020)

Pompe disease diagnosis and management guideline
por: Kishnani, Priya S., et al.
Publicado: (2006)

Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease
por: Sun, Baodong, et al.
Publicado: (2014)

The Pompe Registry: tracking Pompe disease symptoms in a broad patient population
por: Byrne, B, et al.
Publicado: (2008)

Pregnancy Outcomes in Late Onset Pompe Disease
por: Goker-Alpan, Ozlem, et al.
Publicado: (2020)

Crim1 suppresses left ventricular hypertrophy
por: Yang, Long, et al.
Publicado: (2019)

The Outcome of Infantile Onset Pompe Disease in South of Iran
por: Moravej, Hossein, et al.
Publicado: (2016)

The infantile-onset form of Pompe disease: an autopsy diagnosis
por: dos Santos, Otávio César Cruz, et al.
Publicado: (2015)

Atypical Infantile-onset Pompe Disease with Hypertrophic Cardiomyopathy
por: Quan, Jun-Jun, et al.
Publicado: (2017)

Nystagmus in infantile Pompe disease: a new feature?
por: Turco, Emanuela Claudia, et al.
Publicado: (2020)

Development of a fluorometric microtiter plate-based enzyme assay for arylsulfatase B (MPS VI) using dried blood spots
por: Ullal, Anirudh J., et al.
Publicado: (2014)

Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives
por: El Haddad, Léa, et al.
Publicado: (2023)

Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots
por: Ullal, Anirudh J., et al.
Publicado: (2014)

Incidence of infantile Pompe disease in the Maroon population of French Guiana
por: Elenga, Narcisse, et al.
Publicado: (2018)

Essential Role of CRIM1 on Endometrial Receptivity in Goat
por: Yang, Diqi, et al.
Publicado: (2021)

Use of the patient-reported outcomes measurement information system (PROMIS®) to assess late-onset Pompe disease severity
por: Harfouche, Melodi, et al.
Publicado: (2020)

Crim1 regulates integrin signaling in murine lens development
por: Zhang, Ying, et al.
Publicado: (2016)

Small-Fiber Neuropathy in Pompe Disease: First Reported Cases and Prospective Screening of a Clinic Cohort
por: Hobson-Webb, Lisa D., et al.
Publicado: (2015)

Muscle ultrasound in patients with late-onset Pompe disease identified by newborn screening
por: Jackson, David G., et al.
Publicado: (2023)

Measurement Properties of 2 Novel PROs, the Pompe Disease Symptom Scale and Pompe Disease Impact Scale, in the COMET Study
por: Dimachkie, Mazen M., et al.
Publicado: (2023)

Dysregulation of Multiple Facets of Glycogen Metabolism in a Murine Model of Pompe Disease
por: Taylor, Kristin M., et al.
Publicado: (2013)

GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry
por: Reuser, Arnold J. J., et al.
Publicado: (2019)

Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease
por: Wang, Jason, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8b0g11c56sj04s0oviof82io36